Overview

SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.2
USERS' SCORE
Good
Based on 27 Reviews
8.6
Supplement Facts
Serving Size: 2 Marine Softgels
Amount Per Serving
%DV
Calories
20
 
Total Fat
2 g
3%**
Fish Oil ConcentrateTotal Omega-3 Fatty Acids as Ethyl EstersEPA (EicosaPentaenoic Acid), min.DHA (DocosaHexaenoic Acid), min.
2000 mg1400 mg800 mg400 mg
††††

Top Medical Research Studies

We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.

For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
We investigated how eicosapentaenoic acid (EPA) affects heart rhythm, particularly in the context of high-fat diets. In our study, mice were divided into two groups: one received a high-fat diet, while the other’s diet was supplemented with EPA for eight weeks.

We observed that the mice on a high-fat diet experienced severe heart rhythm issues, such as bradycardia and atrial fibrillation (AF). In contrast, the EPA group showed significantly less AF and better heart function. These results suggest that including EPA in the diet could be a promising strategy to support heart health and reduce the risk of arrhythmias.
Read More
9
High-dose omega-3 improves heart function
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.

Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.

However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More

Most Useful Reviews

9.5
Cholesterol reduction
I purchased this Omega 3 for my husband due to his atherosclerosis and heart attack. Remarkably, his cholesterol dropped to 3 while taking it alongside his statin medications.
Read More
9.5
Best quality omega
This is my consistent choice for Omega. It undoubtedly benefits heart function, reduces cholesterol, improves hair condition, and lessens chronic inflammation. The product offers the best quality and optimal dosage. I highly recommend it to others for use.
Read More
8.3
High-quality omega
Prescribed by my cardiologist, I chose this omega with a high EPA content to effectively support my heart's blood vessels. It's derived from anchovies, avoiding heavy metals. This large dosage makes it the best choice for me.
Read More

Medical Researches

SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.2
  • All Researches
We analyzed the impact of different fatty acid-derived acylcarnitines on heart health. The study found that saturated and monounsaturated acylcarnitines, especially trans-elaidoylcarnitine, significantly impaired heart function and mitochondrial activity, leading to cardiotoxicity.

In contrast, omega-3-derived acylcarnitines, like eicosapentaenoylcarnitine and docosahexaenoylcarnitine, were found to be safe, having little to no negative effect on heart function and cell viability. Overall, this research suggests that omega-3 fatty acids may be a safer option for those facing cardiac challenges.
Read More
9
High-dose omega-3 improves heart function
We explored how omega-3 polyunsaturated fatty acids (PUFAs) can help manage heart failure by analyzing 14 randomized controlled trials involving over 9,000 participants.

Our findings revealed that high doses—between 2000 and 4000 mg daily—taken for at least a year, remarkably improved heart function.

However, lower doses or shorter treatment periods didn’t show the same benefits. Notably, there were no increased risks of adverse events or dropout rates in those taking omega-3 compared to control groups.
Read More
We examined the relationship between plasma omega-3 levels and heart failure (HF), focusing on how this affects mortality in patients with existing HF. Our analysis of the UK Biobank, which included nearly 272,000 participants without HF, showed that higher omega-3 levels were linked to a 21% lower risk of developing HF over nearly 14 years.

For those already diagnosed with HF, higher omega-3 levels significantly reduced the risk of all-cause and cardiovascular mortality by around 50%. These findings suggest that boosting omega-3 intake could be beneficial for heart health.
Read More
9
Omega-3 benefits African Americans’ heart health
We observed that the role of omega-3 fatty acids in heart health showed promising results specifically for African Americans. By comparing matched groups from the VITAL trial, we found that omega-3 supplementation significantly reduced the risk of myocardial infarction in African Americans, while no such benefit was seen in non-Hispanic whites.

This suggests that genetic or lifestyle factors may influence the effectiveness of these supplements. Our findings highlight the importance of further research to better understand how race affects responses to omega-3 supplementation.
Read More
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.

Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.

This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Read More

User Reviews

USERS' SCORE
Good
Based on 27 Reviews
8.6
  • All Reviews
  • Positive Reviews
  • Negative Reviews
9.5
Cholesterol reduction
I purchased this Omega 3 for my husband due to his atherosclerosis and heart attack. Remarkably, his cholesterol dropped to 3 while taking it alongside his statin medications.
Read More
9.5
Best quality omega
This is my consistent choice for Omega. It undoubtedly benefits heart function, reduces cholesterol, improves hair condition, and lessens chronic inflammation. The product offers the best quality and optimal dosage. I highly recommend it to others for use.
Read More
8.3
High-quality omega
Prescribed by my cardiologist, I chose this omega with a high EPA content to effectively support my heart's blood vessels. It's derived from anchovies, avoiding heavy metals. This large dosage makes it the best choice for me.
Read More
9.5
Enhances cognitive ability
Pure Omega 3 fish oil improves cardiovascular health by lowering blood lipids, reducing the risk of heart disease, and enhancing cognitive function, memory, and learning abilities. It also promotes joint health, boosts immunity, and has anti-inflammatory effects, making it a vital supplement for holistic health.
Read More
9.5
Exceptional heart health
I am extremely satisfied with the Omega supplements I purchased. I have seen substantial improvements in my heart health and overall well-being since incorporating these supplements into my daily routine. The benefits for heart health are evident, and I appreciate the high-quality ingredients. I highly recommend them to anyone wanting to support their heart health with a reliable and premium product.
Read More

Frequently Asked Questions

No FAQs are available for this product and symptom.

References

  1. Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. doi:10.1002/biof.70014
  2. Xu J, Peng T, Kong L, Wei N. A global analysis of the burden of ischemic heart disease attributable to diet low in ω-3 fatty acids between 1990 and 2021. BMC Cardiovasc Disord. 2025;25:188. doi:10.1186/s12872-025-04620-z
  3. Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. doi:10.1016/j.jphyss.2025.100014
  4. Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. doi:10.1186/s12944-025-02500-1
  5. Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
  6. Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
  7. Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. doi:10.1515/jcim-2024-0427
  8. Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. doi:10.1016/j.foodchem.2024.142498
  9. Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. doi:10.1016/j.mayocp.2024.08.007
  10. Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. doi:10.1017/S0007114524002708
  11. Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
  12. Ryuno Y, Kobayashi JI, Fujimoto Y, Dotare T, Matsue Y, et al. Effect of an Enteral Formula Enriched With ω-3 Fatty Acids, Carnitine, and Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a Dahl Rat Heart Failure Model. J Cardiovasc Pharmacol. 2024;84:590. doi:10.1097/FJC.0000000000001637
  13. Sun S, Hara A, Johnstone L, Hallmark B, Watkins JC, et al. Optimal Pair Matching Combined with Machine Learning Predicts a Significant Reduction in Myocardial Infarction Risk in African Americans Following Omega-3 Fatty Acid Supplementation. Nutrients. 2024;16. doi:10.3390/nu16172933
  14. Ahmadi M, Askari VR, Shahri B, Mousavi Noghab SM, Jarahi L, et al. Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:881. doi:10.1007/s00210-024-03330-1
  15. Chen HC, Tai CJ, Huang JY, Kuo TA, Huang YD, et al. Associations of fish oil with cardiovascular disease events: results from the Taiwan longitudinal study in aging. BMC Public Health. 2024;24:1979. doi:10.1186/s12889-024-19512-8
  16. Yu Y, Gao M, Xu H. Ginger Extract and Omega-3 Fatty Acids Supplementation: A Promising Strategy to Improve Diabetic Cardiomyopathy. Physiol Res. 2024;73:351.
  17. Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
  18. Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
  19. Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
  20. Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
  21. Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
  22. Capece U, Gugliandolo S, Morciano C, Avolio A, Splendore A, et al. Erythrocyte Membrane Fluidity and Omega-3 Fatty Acid Intake: Current Outlook and Perspectives for a Novel, Nutritionally Modifiable Cardiovascular Risk Factor. Nutrients. 2024;16. doi:10.3390/nu16244318
  23. Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
  24. O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
  25. Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
  26. Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
  27. Amangurbanova M, Daher R, Asbeutah AA, Vemuri B, Mirza H, et al. Higher epicardial adipose tissue volume is associated with higher coronary fatty plaque volume and is regulated by waist circumference but not EPA+DHA supplementation. J Clin Lipidol. 2024;18:e773. doi:10.1016/j.jacl.2024.06.006
  28. Kumakura H, Funada R, Matsuo Y, Iwasaki T, Nakashima K, et al. Eicosapentaenoic Acid Level Predicts Long-Term Survival and Cardiovascular or Limb Event in Peripheral Arterial Disease. Ann Vasc Dis. 2024;17:135. doi:10.3400/avd.oa.23-00079
  29. Xiao Y, Chen Y, Pietzner A, Elbelt U, Fan Z, et al. Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies. Nutrients. 2024;16. doi:10.3390/nu16111610
  30. Asbeutah AA, Daher R, Malik A, Hariri E, Alfaddagh A, et al. The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial. Am J Cardiol. 2024;225:98. doi:10.1016/j.amjcard.2024.06.001
  31. Sudo Y, Morimoto T, Tsushima R, Oka A, Sogo M, et al. Eicosapentaenoic Acid and the Outcomes in Older Patients Undergoing Atrial Fibrillation Ablation. J Am Heart Assoc. 2024;13:e033969. doi:10.1161/JAHA.123.033969
  32. Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150:425. doi:10.1161/CIRCULATIONAHA.123.065520
image